Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Sep 23, 2024

Dr. Harven DeShield is the CEO and Co-Founder of Vivacelle Bio, which is developing a nanoparticle-based treatment called VBI-S to address the underlying causes of septic shock. The treatment works by efficiently redistributing nitric oxide to help regulate blood pressure and improve organ function, reducing the need for traditional vasopressor treatments. Vivacelle is also developing a product to help address hemorrhagic shock and minimize reperfusion injury.

Harven explains, "There are seven aspects to septic shock - actually eight. So, first, you have an infection. You have to have an infection, whether it is a bacterial, virus, or fungus. And then, eventually, they give you fluids—your blood pressure drops. And so, they try to correct that by giving you fluids. And when the fluids fail, then you transition from sepsis to septic shock."

"Then, you are also dealing with the fact that they put you on vasopressors once you get into septic shock. When they put you on vasopressors, that creates another whole realm of problems, which I can get into later. But, essentially, they have some serious toxicity effects, including reducing cardiac output. It causes cardiac arrhythmia and blood clots and can even lead somebody to go into hemorrhagic shock. So, you have the infection problems, you have the relative and absolute hypovolemia problem."

"Our product, for example, works within, and I’m using phase 2a - we see results in as little as 90 minutes, in terms of, at least, correcting the blood pressure. And it really can be very severe, and time is of the essence. There used to be something they called the "golden hour”.  This means you have an hour, depending on how low your blood pressure is. Now, some people call it the "platinum ten minutes".

#VivacelleBio #SepticShock #Sepsis #Hypovolemia #UrgentCareTreatment

vivicellebio.com

Download the transcript here

Vivacelle